21,076 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Cibc World Markets Corp

Cibc World Markets Corp bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 21,076 shares of the biotechnology company's stock, valued at approximately $361,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ADMA. State Street Corp boosted its stake in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC raised its holdings in ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after buying an additional 137,989 shares during the last quarter. Perpetual Ltd bought a new stake in ADMA Biologics during the 4th quarter valued at $62,300,000. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics during the 3rd quarter valued at $61,858,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 0.1 %

NASDAQ:ADMA traded down $0.02 during trading hours on Friday, hitting $20.26. The company had a trading volume of 2,360,170 shares, compared to its average volume of 3,524,376. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 52 week low of $5.90 and a 52 week high of $23.64. The company has a market capitalization of $4.79 billion, a PE ratio of 72.36 and a beta of 0.60. The stock has a 50-day moving average price of $17.05 and a 200 day moving average price of $18.13.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.